NOTCH1 signalling contributes to defective remyelination by impairing differentiation of oligodendrocyte progenitor cells (OPCs). Here we report that IL-17 stimulation induces NOTCH1 activation in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio IL-17 inhibitors have recently ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Although TNF inhibitors remain the first choice biologic ...

Protagonist Therapeutics Inc. has selected PN-881, an oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...